OraSure Technologies (OSUR) Earning Somewhat Favorable Press Coverage, Report Finds

Media headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.264610511488 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of OraSure Technologies (NASDAQ OSUR) opened at $18.28 on Tuesday. The firm has a market capitalization of $1,108.65, a P/E ratio of 35.84, a price-to-earnings-growth ratio of 5.10 and a beta of 1.43. OraSure Technologies has a 52-week low of $10.70 and a 52-week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The firm had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The firm’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 earnings per share. research analysts forecast that OraSure Technologies will post 0.29 EPS for the current fiscal year.

Several brokerages have recently issued reports on OSUR. BidaskClub downgraded OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 15th. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, February 13th. Canaccord Genuity reiterated a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, Jefferies Group downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $22.25.

ILLEGAL ACTIVITY NOTICE: This story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/02/20/orasure-technologies-osur-earning-somewhat-favorable-press-coverage-report-finds.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply